Tamtam Try Tamtam free
Ambu logo

Ambu account plan

Innovative single-use medical devices

At a glance

Danish maker of single-use endoscopes and anesthesia and patient-monitoring devices: DKK 6,471m revenue in FY2025/26, ~5,400 employees.

Ambu A/S, founded in 1937 and based in Ballerup near Copenhagen, develops, manufactures and sells medical devices and positions itself as the global leader in single-use endoscopy, with 60%+ share of the single-use market. It sells in 60+ markets, with North America at 50% of revenue and Europe at 40%, makes its products in four factories (Mexico, Malaysia, China, U.S.) and has ~5,400 employees. In FY2025/26 (to 30 September 2026) revenue was DKK 6,471m, organic growth 10.1%, EBIT DKK 851m (13.2% margin) and net profit DKK 642m. Its class B shares are listed on Nasdaq Copenhagen, while the Hesse founding family holds 17.3% of capital and 61.5% of votes through unlisted A shares.

Business units

Strategic priorities

ZOOM AHEAD: global endoscopy leadership
The 2030 strategy launched on 1 October 2025 targets 11-13% organic revenue CAGR to 2029/30 (Endoscopy Solutions 15-20%, A&PM 3-5%), an EBIT margin of 20%+ and cash conversion of 40%+.
Converting endoscopy to single-use
Single-use is only 3-4% of a DKK 190bn endoscopy opportunity, with penetration of 20% in Respiratory, 10% in Urology, 2-4% in ENT and below 1% in GI; Ambu plans to Win in Respiratory and Urology, Grow in ENT and Unlock GI.
New endoscope generations in two years
Over the next two financial years Ambu plans more than seven new solutions, including four new generations of endoscopes across Respiratory, Urology, ENT and GI, starting with an ENT rhinolaryngoscope.
EndoIntelligence software, AI and EMR integration
Ambu is extending its EndoIntelligence platform beyond hardware into software, AI, cybersecurity and hospital EMR connectivity, helped by the TIMS Medical acquisition and AI partnerships with U.S. medical institutions for bronchoscopy.
Selling to hospital decision makers
The U.S. commercial organization was rebuilt from April 2026 around hospitals and health-system decision makers, with separate Urology and ENT sales forces.
Margin expansion through the OPEX ratio
EBIT is to grow faster than revenue every year, with 80% of the margin expansion coming from the OPEX ratio (mainly administration and distribution costs), alongside standardization of Finance, Operations and R&D processes ahead of core-system upgrades.

Latest results

In Q4 2025/26 organic growth reached 13.9%, with Endoscopy Solutions at 21.2% and A&PM at 2.8%, and an EBIT margin of 17.2% that included DKK 85m of tariff refunds. For the full year FY2025/26, revenue rose to DKK 6,471m (DKK 6,037m) with 10.1% organic growth, the EBIT margin was 13.2% (13.0%) and FCF before acquisitions was DKK 487m (cash conversion 39%). Guidance for 2026/27 is organic growth of 9.5-11.5% (Endoscopy Solutions around 15%), an EBIT margin of 13-15% assuming a tariff expense of 1% of revenue and no refunds, and cash conversion of ~30% on higher capex ahead of the new endoscope launches.

Investments and deals

Acquisition of TIMS Medical
Acquired on 11 September 2026 for an enterprise value of USD 45m plus up to USD 20m earn-out: U.S. ENT imaging, reporting and documentation software with ~7,000 U.S. hospital installations, 56 employees and DKK ~97m of annual revenue.
Mexico factory ramp-up
Production is moving from Malaysia to Mexico to balance the footprint, mitigate tariffs and serve North America; the Mexico factory is above 50% utilization.
Capex for launches and automation
Investments in property, plant, equipment and right-of-use assets were DKK 314m in 2025/26 (DKK 185m); capex rises in 2026/27 for new production lines and manufacturing automation, and innovation spending is more than DKK 500 million.
Shareholder returns
DKK 559m was returned in 2025/26 (DKK 109m dividend, DKK 450m buybacks); for 2026/27 a DKK 151m dividend and a DKK 400m buyback are planned.

Challenges and risks

Anesthesia volume losses in the U.S.
A&PM grew only 0.4% organically in FY2025/26 after price increases cost volumes at selected U.S. accounts under non-exclusive contracts; the effect annualizes into 2026/27.
Competition and pricing in Urology
Ureteroscopy is a crowded single-use market where share gains are slower than planned, and strategic price initiatives against low-cost players in cystoscopy weighed on gross margin.
Tariffs and currency
Tariff expense was around DKK 160m (2.5% of revenue) in 2025/26, with an expected drag of about 1% of revenue in 2026/27; about 51% of revenue is invoiced in USD, which management calls the biggest external factor.
Supply, quality and cybersecurity risk
The annual report names disruption at a manufacturing site or single-source supplier, quality processes and cybersecurity and IT resilience among its main risks; Ambu is dual sourcing critical components.
Elevated working capital and lower cash conversion
Net working capital was 23% of revenue at 30 September 2026, above the ~20% target on elevated inventory, and cash conversion is guided at ~30% for 2026/27, below the 40% target.

What leadership says

“We delivered another strong quarter, with 16% growth in Endoscopy Solutions and market share gains in all endoscopy areas, reinforcing Ambu's leadership in the conversion to single-use endoscopes.”

Britt Meelby Jensen, CEO · Interim Report for Q3 2025/26, 2026-08-25

“over the next 2 financial years, so the next 24 months, we are going to launch new generations of endoscopes across our 4 main endoscopy areas”

Britt Meelby Jensen, CEO · Q4 and full-year 2025/26 earnings call, 2026-11-05

“a very sticky point for customers. So once we are integrated, they stay with Ambu”

Henrik Skak Bender, CFO · On EMR integration, Q4 and full-year 2025/26 earnings call, 2026-11-05

“cost inflation still is not a big theme internally in Ambu”

Henrik Skak Bender, CFO · Q3 2025/26 earnings call, 2026-08-26

Where a supplier can help

Hospital IT, EMR and AI integration
The EndoIntelligence priority and the TIMS Medical acquisition call for EMR connectivity, cybersecurity, imaging software and AI partners, an area the CFO calls sticky for customers.
Manufacturing automation and the Mexico ramp-up
Higher capex for new production lines, manufacturing automation and the transfer of production from Malaysia to Mexico open room for automation, equipment and industrial service suppliers.
Administration and distribution efficiency
With 80% of planned margin expansion to come from the OPEX ratio and core-system upgrades ahead, suppliers of ERP, finance and logistics tools and process automation fit the margin priority.
Selling to hospital decision makers
The rebuilt U.S. commercial organization, targeting hospital administration and health-system decision makers with separate Urology and ENT sales forces, could use sales enablement, health-system data and CRM tools.
Supply chain resilience
Single-source supplier risk, dual sourcing of critical components and tariff exposure make component suppliers and trade compliance services relevant.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Ambu?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Ambu

What does Ambu do?

Ambu develops, manufactures and sells medical devices, mainly single-use endoscopes for respiratory, urology, ENT and GI procedures, plus anesthesia and patient-monitoring products. It claims 60%+ share of the single-use endoscopy market.

What is Ambu's revenue?

Revenue was DKK 6,471m in FY2025/26 (to 30 September 2026), with 10.1% organic growth and an EBIT margin of 13.2%. Endoscopy Solutions made up 64% of revenue.

How many employees does Ambu have?

Ambu has ~5,400 employees across 20+ countries; the average number of employees in FY2025/26 was 5,569.

What is Ambu's strategy?

ZOOM AHEAD, launched in October 2025, aims at global endoscopy leadership by converting procedures to single-use endoscopes, with 2029/30 targets of 11-13% organic revenue CAGR and an EBIT margin of 20%+.

Who leads Ambu?

Britt Meelby Jensen is CEO (joined 2022) and Henrik Skak Bender is CFO (joined 2024); the board is chaired by Jørgen Falkebo Jensen.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)